Evidence map›Paper›PMID 37739233›Full record

ArticleOphthalmology2024

Developing a Continuous Severity Scale for Macular Telangiectasia Type 2 Using Deep Learning and Implications for Disease Grading.

Yue Wu, Catherine Egan, Abraham Olvera-Barrios, Lea Scheppke, Tunde Peto, Peter Charbel Issa, Tjebo F C Heeren, Irene Leung, Anand E Rajesh, Adnan Tufail and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Yue WuDepartment of Ophthalmology, University of Washington, Seattle, Washington; The Roger and Angie Karalis Johnson Retina Center, Seattle, Washington.
Catherine EganMoorfields Eye Hospital, London, United Kingdom; University College London, Institute of Ophthalmology, London, United Kingdom.
Abraham Olvera-BarriosMoorfields Eye Hospital, London, United Kingdom; University College London, Institute of Ophthalmology, London, United Kingdom.
Lea ScheppkeLowy Medical Research Institute, La Jolla, California; The Scripps Research Institute, La Jolla, California.
Tunde PetoCenter for Public Health, Queen's University Belfast, Belfast, United Kingdom.
Peter Charbel IssaOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Tjebo F C HeerenMoorfields Eye Hospital, London, United Kingdom.
Irene LeungMoorfields Eye Hospital, London, United Kingdom.
Anand E RajeshDepartment of Ophthalmology, University of Washington, Seattle, Washington; The Roger and Angie Karalis Johnson Retina Center, Seattle, Washington.
Adnan TufailMoorfields Eye Hospital, London, United Kingdom; University College London, Institute of Ophthalmology, London, United Kingdom.
Cecilia S LeeDepartment of Ophthalmology, University of Washington, Seattle, Washington; The Roger and Angie Karalis Johnson Retina Center, Seattle, Washington.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Martin FriedlanderLowy Medical Research Institute, La Jolla, California; The Scripps Research Institute, La Jolla, California.
Aaron Y LeeDepartment of Ophthalmology, University of Washington, Seattle, Washington; The Roger and Angie Karalis Johnson Retina Center, Seattle, Washington. Electronic address: leeay@uw.edu.
University of Washington · USMoorfields Eye Hospital NHS Foundation Trust · GBMoorfields Eye Hospital · GBScripps Research Institute · USNational Institutes of Health · USNuffield Orthopaedic Centre · GBQueen's University Belfast · GB

Funding

Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHRISTOPHER DIRK KEENE · 2021 to 2026
$80.4M
Aging eyes and aging brains in studying alzheimer's disease: Modern ophthalmic data collection in the adult changes in thought (ACT) studyR01AG060942 · NIA · WASHINGTON UNIVERSITY · PI Cecilia Sungmin Lee · 2019 to 2026
$39.4M
Bridge2AI:Salutogenesis Data Generation ProjectOT2OD032644 · OD · WASHINGTON UNIVERSITY · PI BAXTER, SALLY LIU, CHUTE, CHRISTOPHER G · 2022 to 2025
$32.7M
Epidemiology and clinical outcomes of diabetic macular edemaK23EY029246 · NEI · UNIVERSITY OF WASHINGTON · PI LEE, AARON · 2018 to 2022
$1.1M
NEI NIH HHS K23 EY029246NIA NIH HHS R01 AG060942NIA NIH HHS U19 AG066567NIH HHS OT2 OD032644
6 · The paper itself

Abstract

purposeDeep learning (DL) models have achieved state-of-the-art medical diagnosis classification accuracy. Current models are limited by discrete diagnosis labels, but could yield more information with diagnosis in a continuous scale. We developed a novel continuous severity scaling system for macular telangiectasia (MacTel) type 2 by combining a DL classification model with uniform manifold approximation and projection (UMAP).

designWe used a DL network to learn a feature representation of MacTel severity from discrete severity labels and applied UMAP to embed this feature representation into 2 dimensions, thereby creating a continuous MacTel severity scale.

participantsA total of 2003 OCT volumes were analyzed from 1089 MacTel Project participants.

methodsWe trained a multiview DL classifier using multiple B-scans from OCT volumes to learn a previously published discrete 7-step MacTel severity scale. The classifiers' last feature layer was extracted as input for UMAP, which embedded these features into a continuous 2-dimensional manifold. The DL classifier was assessed in terms of test accuracy. Rank correlation for the continuous UMAP scale against the previously published scale was calculated. Additionally, the UMAP scale was assessed in the κ agreement against 5 clinical experts on 100 pairs of patient volumes. For each pair of patient volumes, clinical experts were asked to select the volume with more severe MacTel disease and to compare them against the UMAP scale.

main outcome measuresClassification accuracy for the DL classifier and κ agreement versus clinical experts for UMAP.

resultsThe multiview DL classifier achieved top 1 accuracy of 63.3% (186/294) on held-out test OCT volumes. The UMAP metric showed a clear continuous gradation of MacTel severity with a Spearman rank correlation of 0.84 with the previously published scale. Furthermore, the continuous UMAP metric achieved κ agreements of 0.56 to 0.63 with 5 clinical experts, which was comparable with interobserver κ values.

conclusionsOur UMAP embedding generated a continuous MacTel severity scale, without requiring continuous training labels. This technique can be applied to other diseases and may lead to more accurate diagnosis, improved understanding of disease progression, and key imaging features for pathologic characteristics. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Deep LearningDiabetic RetinopathyRetinal TelangiectasisDisease ProgressionFluorescein AngiographyHumansTomography, Optical CoherenceContinuous scaleDeep learningFeature embeddingMacTelOCT

Identifiers

PMID37739233
PMCPMC10841914
OpenAlexW4386880692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.